ID

34473

Description

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach; ODM derived from: https://clinicaltrials.gov/show/NCT01138527

Lien

https://clinicaltrials.gov/show/NCT01138527

Mots-clés

  1. 17/01/2019 17/01/2019 -
  2. 27/05/2019 27/05/2019 -
Détendeur de droits

see on clinicaltrials.gov

Téléchargé le

17 janvier 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Prostate Cancer NCT01138527

Eligibility Prostate Cancer NCT01138527

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
biopsy-proven diagnosis of adenocarcinoma of the prostate
Description

ID.1

Type de données

boolean

subject will sign a consent form prior to study entry
Description

ID.2

Type de données

boolean

radical prostatectomy and histopathological exam planned
Description

ID.3

Type de données

boolean

the time interval between last biopsy and the mr exam must be at least 4 weeks
Description

ID.4

Type de données

boolean

the time interval between mr exam and radical prostatectomy should not exceed 12 weeks
Description

ID.5

Type de données

boolean

Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
subjects who are unable to give valid informed consent
Description

ID.6

Type de données

boolean

subjects who are unwilling or unable to undergo an mr exam, including subjects with contra-indications to mr exams
Description

ID.7

Type de données

boolean

therapy or surgical procedure applied to the prostate or to other organs in vicinity to the prostate: among the therapies preventing inclusion are any form of radiation therapy, cryo-therapy, thermal-therapy, therapy based on any other medication (including hormonal therapy).
Description

ID.8

Type de données

boolean

patients under hormone deprivation therapy.
Description

ID.9

Type de données

boolean

Similar models

Eligibility Prostate Cancer NCT01138527

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
biopsy-proven diagnosis of adenocarcinoma of the prostate
boolean
ID.2
Item
subject will sign a consent form prior to study entry
boolean
ID.3
Item
radical prostatectomy and histopathological exam planned
boolean
ID.4
Item
the time interval between last biopsy and the mr exam must be at least 4 weeks
boolean
ID.5
Item
the time interval between mr exam and radical prostatectomy should not exceed 12 weeks
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
subjects who are unable to give valid informed consent
boolean
ID.7
Item
subjects who are unwilling or unable to undergo an mr exam, including subjects with contra-indications to mr exams
boolean
ID.8
Item
therapy or surgical procedure applied to the prostate or to other organs in vicinity to the prostate: among the therapies preventing inclusion are any form of radiation therapy, cryo-therapy, thermal-therapy, therapy based on any other medication (including hormonal therapy).
boolean
ID.9
Item
patients under hormone deprivation therapy.
boolean

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial